Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women

Journal of Clinical Pharmacology

Volumn 38, Issue 2, 1998, Pages 144-150

  Suri, Ajit ^a,b   Forbes, William P ^a   Bramer, Steven L ^a  

^a Otsuka America Pharmaceutical ^*  (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDRO 6 [4 [1 (4 HYDROXYCYCLOHEXYL) 1H TETRAZOL 5 YL]BUTOXY] 2(1H) QUINOLINONE; ALBUMIN; CILOSTAZOL; DEHYDROCILOSTAZOL; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; GENDER; HEADACHE; HUMAN; INTERMITTENT CLAUDICATION; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE;

EID: 0031906875     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04403.x     Document Type: Article

References (12)

1. Kimura Y, Tani T, Kanbe T, Watanabe K: Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneim Forschr Drug Res 1985;35:1144-1148.
2. Niki T, Mori H: Phase I study of cilostazol: safety evaluation at increasing single doses in healthy volunteers. Arzneim Forschr Drug Res 1985;35:1173-1185.
3. Ferry DG, Campbell AJ, Bland R, Beasley M, Gazeley L, Edwards IR: Pharmacokinetics of primenol in young and elderly subjects. Eur J Clin Pharmacol 1992;43:437-439.
4. Vestal RE, Wood AJ, Branch RA, Shand DG, Wilkinson GR: Effects of age and cigarette smoking on propranol disposition. Clin Pharmacol Ther 1979;26:8-15.
5. Akiyama H, Kudo S, Shimizu T: The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneim Forschr Drug Res 1985;35:1133-1140.
6. Akiyama H, Kudo S, Odomi M, Shimizu T: High-performance liquid chromatographic procedure for the determination of a new antithrombotic and vasodilating agent, cilostazol, in human plasma. J Chromatogr 1985;338:456-459.
7. Jusko WJ: Guidelines for collection and analysis of pharmacokinetic data. In, Evans WE, Schentag JJ, Jusko WJ (eds.): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Spokane, WA: Applied Therapeutics. 1986;2-1-2-43.
8. Boxenbaum H, Battle M: Effective half-life in clinical pharmacology. J Clin Pharmacol 1995;35:763-766.
9. SAS Institute: SAS STAT User's Guide. Version 6, fourth edition, volume 2. Cary, NC: SAS Institute, 1989.
10. Hartley R, Forsythe WI, McLain B, Ng PC, Lucock MD: Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children. Clin Pharmacokinet 1991;20:237-246.
11. Vesell ES, Shiveley CA, Passananti GT: Temporal variations of antipyrine half-life in man. Clin Pharmacol Ther 1977;22:843-852.
12. Belanger PM, Dore F, Perusse F, Labrecque G: Temporal variations in the elimination of antipyrine in normal and adrenalectomized rats. Res Commun Chem Pathol Pharmacol 1980;30:243-252.